Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of 6‑month adalimumab treatment on sick leave and retirement in rheumatoid arthritis
2009-017325-19Phase 4Completed
- Sponsor
- Helsingin Reumakeskus
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Adalimumab + conventional DMARD therapy with Placebo + conventional DMARD therapy (2 arms). Primary endpoint: Number of lost work days due to RA during the 6-month follow-up. Started Dec 2009; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-017325-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017325-19.